J. Goldman & Co’s Alnylam Pharmaceuticals ALNY Stock Holding History

J. Goldman & Co’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-6,800	Closed	-$3.1M	–	553
2025 Q3	$3.1M	Buy	+6,800	New	+$2.77M	0.08%	245
2025 Q2	–	Sell	-21,000	Closed	-$5.67M	–	453
2025 Q1	$5.67M	Buy	+21,000	New	+$5.4M	0.14%	192
2024 Q4	–	Sell	-3,700	Closed	-$1.02M	–	444
2024 Q3	$1.02M	Sell	3,700 -46,600	-93%	-$12.1M	0.03%	294
2024 Q2	$12.2M	Buy	+50,300	New	+$7.94M	0.35%	95
2023 Q1	–	Sell	-20,000	Closed	-$4.75M	–	353
2022 Q4	$4.75M	Buy	+20,000	New	+$4.27M	0.23%	108

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

J. Goldman & Co's ALNY Position: Q1 2026 in Review

J. Goldman & Co sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 3,368 shares — an estimated $1.15M sold.

J. Goldman & Co first reported a position in ALNY in Q1 2025 and held it in 2 quarters. The position peaked at $20M in Q1 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

J. Goldman & Co reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
J. Goldman & Co sold 3,368 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $1.15M.
J. Goldman & Co first reported a position in Alnylam Pharmaceuticals in Q1 2025 and held it in 2 quarters.
J. Goldman & Co's Alnylam Pharmaceuticals position peaked at $20M in Q1 2025.
786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.